Pharmacokinetics of repeated single oral doses of enalapril maleate (MK-421) in normal volunteers. 1984

A E Till, and H J Gomez, and M Hichens, and J A Bolognese, and W R McNabb, and B A Brooks, and F Noormohamed, and A F Lant

Enalapril, the ethyl ester of a potent angiotensin converting enzyme inhibitor, enalaprilat, was administered to healthy volunteers as a capsule containing 10 mg of the maleate salt, every 24h for eight doses. Serum profiles show little accumulation of enalaprilat following eight daily doses of enalapril maleate. An average effective half-life for accumulation of approximately 11h was calculated from urine data. Comparison of observed 24-h urinary recoveries of enalaprilat to predicted steady-state recovery indicates that an 'average' steady state for enalaprilat is attained by the third or fourth dose of enalapril maleate. Statistical comparison of daily urinary recoveries, as well as Cmin values for enalaprilat, confirm this. Observed fluctuations in serum and urine data during apparent steady state suggest some day-to-day variability in the absorption of enalapril maleate and/or its hydrolysis to enalaprilat. An accumulation ratio of 1.3 for enalaprilat was calculated from the predicted steady-state urinary recovery and observed urinary recovery for dose one.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D004151 Dipeptides Peptides composed of two amino acid units. Dipeptide
D004656 Enalapril An angiotensin-converting enzyme inhibitor that is used to treat HYPERTENSION and HEART FAILURE. Enalapril Maleate,MK-421,MK421,Renitec,Renitek,MK 421,Maleate, Enalapril
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000959 Antihypertensive Agents Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. Anti-Hypertensive,Anti-Hypertensive Agent,Anti-Hypertensive Drug,Antihypertensive,Antihypertensive Agent,Antihypertensive Drug,Anti-Hypertensive Agents,Anti-Hypertensive Drugs,Anti-Hypertensives,Antihypertensive Drugs,Antihypertensives,Agent, Anti-Hypertensive,Agent, Antihypertensive,Agents, Anti-Hypertensive,Agents, Antihypertensive,Anti Hypertensive,Anti Hypertensive Agent,Anti Hypertensive Agents,Anti Hypertensive Drug,Anti Hypertensive Drugs,Anti Hypertensives,Drug, Anti-Hypertensive,Drug, Antihypertensive,Drugs, Anti-Hypertensive,Drugs, Antihypertensive

Related Publications

A E Till, and H J Gomez, and M Hichens, and J A Bolognese, and W R McNabb, and B A Brooks, and F Noormohamed, and A F Lant
February 1985, The Tohoku journal of experimental medicine,
A E Till, and H J Gomez, and M Hichens, and J A Bolognese, and W R McNabb, and B A Brooks, and F Noormohamed, and A F Lant
August 1982, Lancet (London, England),
A E Till, and H J Gomez, and M Hichens, and J A Bolognese, and W R McNabb, and B A Brooks, and F Noormohamed, and A F Lant
February 1983, Federation proceedings,
A E Till, and H J Gomez, and M Hichens, and J A Bolognese, and W R McNabb, and B A Brooks, and F Noormohamed, and A F Lant
December 1984, The Tohoku journal of experimental medicine,
A E Till, and H J Gomez, and M Hichens, and J A Bolognese, and W R McNabb, and B A Brooks, and F Noormohamed, and A F Lant
November 2012, International journal of clinical pharmacology and therapeutics,
A E Till, and H J Gomez, and M Hichens, and J A Bolognese, and W R McNabb, and B A Brooks, and F Noormohamed, and A F Lant
January 1985, Psychopharmacology,
A E Till, and H J Gomez, and M Hichens, and J A Bolognese, and W R McNabb, and B A Brooks, and F Noormohamed, and A F Lant
December 1998, Journal of clinical pharmacology,
A E Till, and H J Gomez, and M Hichens, and J A Bolognese, and W R McNabb, and B A Brooks, and F Noormohamed, and A F Lant
December 1998, Journal of clinical pharmacology,
A E Till, and H J Gomez, and M Hichens, and J A Bolognese, and W R McNabb, and B A Brooks, and F Noormohamed, and A F Lant
May 1993, Journal of clinical pharmacology,
A E Till, and H J Gomez, and M Hichens, and J A Bolognese, and W R McNabb, and B A Brooks, and F Noormohamed, and A F Lant
April 1982, Life sciences,
Copied contents to your clipboard!